Reviews/Heart Failure Management/Left bundle branch pacing achieves superior resynchronisation versus conventional biventricular cardiac resynchronisation therapy
CRT · HFM-CRT-03 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
This claim says that pacing the heart's left bundle branch resynchronises the failing ventricle better than the standard two-lead (biventricular) approach, both electrically and mechanically. The studies here point in a favourable direction but do not agree. One randomised trial found the heart's pumping fraction improved more with the newer technique [18], and a large observational study found both a narrower electrical signal and better pumping [15], yet another randomised trial found the primary measure of mechanical response was no better [5], and a third randomised trial found the newer approach actually worse than the standard one [13]. The electrical advantage shows up only in the observational data, while the two trials that measured it found no difference. Because the evidence for 'superior on both counts' pulls in opposite directions, the panel did not affirm the claim.
Four sources compare left bundle branch or conduction system pacing against biventricular pacing on resynchronisation surrogates. [18] (randomised, n=40, nonischaemic) shows greater LVEF improvement (mean difference 5.6%; 95% CI 0.3-10.9; P=0.039) and greater LVESV reduction (-24.97 mL). [5] (randomised, n=200) shows a comparable primary echocardiographic response (86.0% vs 81.0%; P=.34) with a higher super-response rate (55.0% vs 36.0%; P<.007). [15] (observational, n=477) shows narrower paced QRS (133 ± 21 ms vs 153 ± 24 ms; P<.001) and greater LVEF (39.7% ± 13% vs 33.1% ± 12%; P<.001). [13] (randomised, n=173) found CSP inferior, with LVEF rising to 35% vs 39% favouring BiVP and comparable QRS improvement. The contested point: The evidence divides on whether superiority holds on both the electrical and mechanical axes at once. Mechanical remodelling favours the newer technique in [18], [5] (super-response only) and [15] but is reversed in the randomised [13]; the electrical advantage appears only in observational [15], while the two randomised trials reporting QRS ([18], [13]) found it comparable between arms.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Internal contradiction: [13], a 173-patient multicentre RCT, found CSP inferior to BiVP for the composite including LVEF change, with LVEF increasing to 35% (CSP) vs 39% (BiVP) — directly opposing the superiority claim on mechanical resynchronisation.
Electrical superiority is largely unsupported: the two RCTs reporting QRS ([18], [13]) found QRS comparable between arms; narrower paced QRS appears only in observational [15], which is subject to selection bias.
Where it remains uncertain. The randomised [13] found conduction system pacing inferior to BiVP (LVEF 35% vs 39%) with comparable QRS improvement, and in [5] the primary echocardiographic response did not differ (86.0% vs 81.0%; P=.34).
Aleatory
The randomised trial most favourable mechanically ([18]) enrolled only 40 patients, so its effect estimate carries wide intervals (95% CI 0.3-10.9 for the LVEF difference) and is sensitive to chance.
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Partial support: the direct echo response measure did not differ; only super-response favoured LBBP.
“The echocardiographic response rates were similar in both groups (86.0% vs 81.0%; P = .34) but the super-response rate was higher in the LBBP group (55.0% vs 36.0%; P < .007).”
Panel auditInternal validity: high · scope of inference: LBBP versus BiVP for death/HF hospitalisation and echocardiographic response in HFrEF with LBBB.Key limitations: resynchronisation per se not reported · China-only centres · echo response rates not different
Supports both electrical (narrower QRS) and mechanical (greater LVEF) resynchronisation, but observational and CSP mixes HBP+LBBAP.
“Paced QRS duration in CSP was significantly narrower than BVP (133 ± 21 ms vs 153 ± 24 ms; P <.001). LVEF improved in both groups during mean follow-up of 27 ± 12 months and was greater after CSP compared to BVP (39.7% ± 13% vs 33.1% ± 12%; P <.001).”
Panel auditInternal validity: medium · scope of inference: CSP versus BVP clinical and resynchronisation outcomes in patients with LVEF ≤35% and CRT indication.Key limitations: observational, not randomised · CSP includes HBP not only LBBP · selection bias possible
Supports mechanical resynchronisation superiority (LVEF, plus greater LVESV reduction) in a randomized LBBP-vs-BiVP comparison, but n=40 and nonischaemic only.
“Intention-to-treat analysis showed significantly higher LVEF improvement at 6 months after LBBP-CRT than BiVP-CRT (mean difference: 5.6%; 95% CI: 0.3-10.9; P = 0.039).”
Panel auditInternal validity: medium · scope of inference: LBBP-CRT versus BiVP-CRT LVEF response in nonischaemic cardiomyopathy with LBBB.Key limitations: very small sample · nonischaemic only · QRS change comparable, not superior · short follow-up
Contradicts the claim: electrical (QRS) improvement comparable, and LVEF increased to 35% with CSP vs 39% with BiVP, favouring BiVP.
“Relative to baseline, both groups had comparable improvements in QRS duration, Kansas City Cardiomyopathy Questionnaire Overall Summary Score, NYHA class, and natriuretic peptide levels.”
Panel auditInternal validity: high · scope of inference: CSP versus BiVP for a hierarchical HF composite and LVEF in HFrEF with LBBB.Key limitations: CSP not purely LBBP · noninferiority design · 12-month follow-up
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Head-to-head RCTs conflict and electrical superiority appears only in observational data, so superiority cannot be affirmed with confidence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Randomised electrical-resynchronisation endpoints for pure LBBP. Electrical superiority appears only in observational [15]; both randomised trials reporting QRS ([18], [13]) found it comparable, leaving the electrical half of the claim unsupported by randomised data. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A powered randomised trial of pure left bundle branch pacing versus BiVP with prespecified paced QRS duration and LV activation time as co-primary electrical endpoints.
Open question: Does pure left bundle branch pacing produce a narrower paced QRS than biventricular pacing in a randomised comparison? Why it is still open: The only narrower-QRS result is observational ([15]); the randomised trials reporting QRS ([18], [13]) found it comparable between arms.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19